Octreotide in Palliative Treatment of Hepatic Metastases: Is it Effective for Clinical Stabilization?

Print
Published on Thursday, 16 January 2014

Introduction

K Pistevou-Gombaki et al. presented their positive experience from the palliative use of octreotide LAR in hepatic metastases from non-neuroendocrine tumors. On the other hand, there are several negative prospective studies of octreotide efficacy in liver metastases and this policy is not accepted from al oncologists. According to this literature controversy and in continuation to the above-mentioned studies, we would like to report our recent experience from the efficient use of octreotide LAR in seven patients with symptomatic liver metastases from non-neuroendocrine tumors and in one female (80-years-old) with duodenal carcinoid.

 

 

About this Letter to the Editor.